Helus Pharma Completes Enrollment in Phase 3 APPROACH Study of HLP003 in Adjunctive Treatment of Major Depressive Disorder Ahead of Schedule
Enrollment continues in EMBRACE, the second pivotal study of the Phase 3 PARADIGM Program
Enrollment continues in EMBRACE, the second pivotal study of the Phase 3 PARADIGM Program
Summary aggregated from GlobeNewswire's public RSS feed. The full reporting belongs to GlobeNewswire — please read it on their site.